GEP-NETs

Apr 26, 2024

2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects.  On 23rd April 2024, the FDA approved LUTATHERA (also known as lutetium Lu 177 dotatate) for the treatment of pediatric patients of 12 years and older with somatostatin receptor (SSTR)-pos...

Feb 21, 2022

A Neuroendocrine tumor is a type of cancer where neuroendocrine cells develop into tumors. Whereas Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) are tumors that arise from neuroendocrine cells in the gut. A Neuroendocrine Tumor grows slowly and aggressively and tends to spread to other parts of the body. ...